Genitourinary Cancer News

The FDA expanded the approval of pembrolizumab to include adjuvant treatment of certain patients with renal cell carcinoma.

First-line nivolumab plus ipilimumab conferred greater long-term clinical benefit than sunitinib for patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

Tivozanib induced a significantly higher disease control rate than sorafenib among patients with relapsed or refractory advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

Nivolumab plus cabozantinib improved outcomes compared with sunitinib regardless of prior nephrectomy among patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

For years, adjuvant therapy for renal cell carcinoma was ‘under future direction’ in any research discussion.

Post-nephrectomy recurrence appeared associated with shorter survival among patients with intermediate-high or high-risk renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

A small trial that compared radiofrequency ablation with stereotactic body radiation therapy for small renal masses resulted in minimal adverse events, according to results presented at International Kidney Cancer Symposium.

According to a new study, immune checkpoint inhibitor-induced myocarditis is highly associated with arrhythmias and ECG findings including new conduction blocks, decreased voltage and repolarization abnormalities.

Most patients with renal cell carcinoma who received commercially available COVID-19 vaccines mounted sufficient antibody response, according to study results presented at International Kidney Cancer Symposium.

Practice type may significantly influence providers’ choice of first-line therapy for metastatic renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.